Recent News

• 10.01.2025 - Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
• 09.29.2025 - Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
• 09.17.2025 - Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
• 09.10.2025 - Ernexa Therapeutics Provides Update on Operational Excellence and Performance
• 09.03.2025 - Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
• 07.09.2025 - Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
• 06.25.2025 - Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
• 06.24.2025 - Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Recent Filings

• 08.18.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.07.2025 - 8-K Current report
• 07.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2025 - EFFECT Notice of Effectiveness
• 06.18.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 06.16.2025 - CORRESP Correspondence
• 06.16.2025 - UPLOAD SEC-generated letter
• 06.12.2025 - 8-K Current report
• 06.11.2025 - S-8 Securities to be offered to employees in employee benefit plans